Download full-text PDF

Source

Publication Analysis

Top Keywords

[diffuse proliferation
4
proliferation bronchial
4
bronchial alveolar
4
alveolar epithelium
4
epithelium peculiar
4
peculiar lesion
4
lesion measles]
4
[diffuse
1
bronchial
1
alveolar
1

Similar Publications

The distinction between choriocarcinoma and residual trophoblastic cell proliferation from a complete hydatidiform mole/invasive mole (CHM/IM) without villi is challenging on curettage materials. We investigated whether SALL4 immunostaining could help differentiate various gestational trophoblastic diseases. Placental site nodules (PSN; n=10), atypical PSN (APSN; n=8), placental site trophoblastic tumors (PSTT; n=9), epithelioid trophoblastic tumors (ETT; n=5), gestational choriocarcinomas (n=31), partial hydatidiform moles (PHM; n=13), CHM/IM (n=47), and nonmolar products of conception (POC) (n=26) were included.

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous metastatic lymphoma that can be treated by targeting angiogenesis. Apolipoprotein C1 (APOC1) plays a significant role in the proliferation and metastasis of various malignant tumors; however, its role in DLBCL-particularly its effects on angiogenesis-remains largely unexplored. This study investigates the correlation between APOC1 expression and patient prognosis in DLBCL.

View Article and Find Full Text PDF

functional validation of anti-CD19 chimeric antigen receptor T cells expressing lysine-specific demethylase 1 short hairpin RNA for the treatment of diffuse large B cell lymphoma.

Front Immunol

January 2025

Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan, China.

Background: Chimeric antigen receptor T (CAR-T) cell therapy is more effective in relapsed or refractory diffuse large B cell lymphoma (DLBCL) than other therapies, but a high proportion of patients relapse after CAR-T cell therapy owing to antigen escape, limited persistence of CAR-T cells, and immunosuppression in the tumor microenvironment. CAR-T cell exhaustion is a major cause of relapse. Epigenetic modifications can regulate T cell activation, maturation and depletion; they can be applied to reduce T cell depletion, improve infiltration, and promote memory phenotype formation to reduce relapse after CAR-T cell therapy.

View Article and Find Full Text PDF

Myoepithelioma-Like Tumor of the Vulva.

Case Rep Pathol

January 2025

Cardio-Thoracic Surgery, Zhangqiu District Hospital, Jinan City, Shandong Province, China.

Myoepithelioma-like tumor of the vulvar region (MELTVR) is a rare mesenchymal tumor that typically arises in the female vulva. Here, we report a case of a 48-year-old woman who presented with a 2-year history of subcutaneous mass in the vulvar region. As the mass rapidly increased in the last 2 months, personal slight swelling pain appeared.

View Article and Find Full Text PDF

Biocompatible Lyotropic Nanocarriers for Improved Delivery of Ascorbyl Tetraisopalmitate in Skincare.

Langmuir

January 2025

The Education Ministry Key Lab of Resource Chemistry, Joint International Research Laboratory of Resource Chemistry, Shanghai Key Laboratory of Rare Earth Functional Materials, College of Chemistry and Materials Science, Shanghai Normal University, 100 Guilin RD, Shanghai 200234, China.

Ascorbyl tetraisopalmitate (VC-IP) is a novel form of ascorbic acid characterized by reduced water solubility due to complete acylation with palmitate. This study investigated the potential cosmetic application of VC-IP when encapsulated in lyotropic liquid crystal nanoparticles (VC-IP LCNPs) by using a high-pressure homogenization (HPH) method. The particle size, zeta potential, and polydispersity index (PDI) of the obtained VC-IP LCNPs were determined as 158.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!